Non-Hodgkin lymphoma includes more than 70 different cancers of the lymphatic system. Some grow slowly and may not need treatment for years; others are aggressive and require immediate chemotherapy. CAR T-cell therapy and targeted drugs have transformed treatment for several types, and many people now live years without disease.
What's actually going on in research
Trials are testing bispecific antibodies that redirect immune cells to kill lymphoma, next-generation CAR T approaches with fewer side effects, BTK inhibitors for certain subtypes, and combinations that may eliminate chemotherapy for some patients. Researchers are also studying minimal residual disease testing to guide treatment decisions and identify people who can stop therapy early.
Bispecific antibodies
These drugs link a person's T cells directly to lymphoma cells, forcing an immune attack. Several are now FDA-approved, and trials are testing them earlier in treatment to reduce the need for chemotherapy.
CAR T engineering
Researchers are developing CAR T cells that cause less severe side effects and work in more patients. Some trials are testing off-the-shelf versions that don't require custom manufacturing.
Chemo-free regimens
Combinations of targeted drugs and immunotherapy are being tested to replace traditional chemotherapy. Early results suggest some patients can achieve remission without the toxicity of chemo.
What to know before you search
Eligibility depends on lymphoma subtype, number of prior treatments, organ function, and sometimes on specific genetic changes in the cancer.
What types of trials are currently open
- Targeted therapy trials — Testing drugs that attack specific proteins on lymphoma cells, such as BTK inhibitors, BCL-2 inhibitors, or antibodies.
- CAR T trials — Studies of genetically modified immune cells, either custom-made from a patient's own cells or off-the-shelf versions.
- Bispecific antibody trials — Testing drugs that link T cells to lymphoma cells to trigger an immune response, often given as infusions or injections.
- Combination trials — Testing whether pairing newer drugs with each other or with low-dose chemotherapy works better than current treatments.
- Maintenance trials — Testing whether continuing treatment after remission prevents relapse, or whether some patients can safely stop therapy based on testing for remaining disease.
Recently added Non-hodgkin Lymphoma trials
Share your medical history and provide blood samples for lymphoma research
The goal of this observational cohort study is to learn how toxin and occupational exposures, germline genetic variation, and immune dysregulation relate to B-cell non-Hodgkin lymphoma among active-duty service members and other Military Health System beneficiaries. The main questions are whether specific exposures and germline variants are associated with B-cell NHL subtype, immune dysfunction, and clinical outcomes. Participants will complete exposure and medical-history surveys, provide biospecimens for immune and genomic testing, and may be followed annually for up to 3 years.
A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy
This study is designed to evaluate the efficacy and safety of reduced-intensity radiotherapy for stage I/II low-risk nasal-type NK/T-cell lymphoma that has achieved complete remission after chemotherapy.
Find Non-hodgkin Lymphoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.